UNSPSC 51372031: Morphine hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C17H19NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J28GE0ROVX, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, hydrochloride, (5-alpha,6-alpha)- but more generally known as morphine hydrochloride, which bears US NIH Compound Identifier 5464110. European Medicines Agency schedules Morphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14596MIG.

UNSPSC 51372031 Morphine hydrochloride is a Commodity code that encompasses opioid pharmaceutical products procured by state and local health agencies, correctional systems, and public health authorities for clinical, emergency response, and harm-reduction programs. Recent state and local opportunities under this code reflect demand across naloxone procurement, generic pharmaceutical supply agreements, and direct-to-manufacturer pharmacy initiatives. Seminole County, Florida is procuring naloxone (a morphine antagonist) and drug deactivation systems through competitive bidding, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is sourcing generic multi-source pharmaceuticals including controlled substances through multiple-award RFPs distributed via authorized wholesalers. The Texas Health and Human Services Commission has issued an RFI to explore direct-to-manufacturer prescription programs that would include opioid and other pharmaceutical categories. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing consortia. These procurement vehicles typically require vendors to maintain DEA licensing, comply with FDA cGMP and Drug Supply Chain Security Act (DSCSA) requirements, demonstrate NDC and wholesaler relationships, and carry comprehensive insurance including professional liability coverage.

Geographic activity concentrates in Florida, Minnesota (serving multiple states including Oregon through MMCAP), and Texas, with procurement spanning both emergency-response and routine supply channels. Representative recent opportunities include Seminole County's IFB 60459723LAS (RFP posted June 30, 2026, due July 26, 2023, seeking 1,900 units of naloxone annually with quarterly deliveries); MMCAP's S1070000015802 (RFP posted January 20, 2026, due March 26, 2026, establishing multiple contracts for generic pharmaceuticals effective July 1, 2026, with price competitiveness weighted at 75 percent of evaluation); and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs). Multistate cooperative purchasing agreements dominate the landscape, with contracts typically running two years with renewal options and performance penalties of $200 to $1,500 per compliance violation. Vendors must be authorized to distribute through established pharmaceutical wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and meet strict supply-chain security and manufacturing-practice certifications.